Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

• Status: Terminated
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Collaborators: Northwestern University; Temple University; University of Southern Mississippi
• Treatments: Citalopram; Dexetimide; Serotonin; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• Diagnosis of Borderline Personality Disorder

• Current Major Depression

Exclusion Criteria:

• Past 2 months SSRI use

• Past 6 months non-SSRI antidepressant use

• Past 2 months initiation of psychotherapy

• Lifetime bipolar disorder, organic disorder, psychotic disorder

• Current alcohol or drug dependence

• Current severe suicidal / homicidal ideation necessitating immediate medical intervention

• Currently pregnancy or nursing

• Unable or unwilling to cooperate with study protocol